Peripheral vascular disease articles


TEATE Trial: Urine Alkalinization as a Target to Prevent Contrast-Associated Kidney Injury

TEATE Trial: Urine Alkalinization as a Target to Prevent Contrast-Associated Kidney Injury

Acute kidney injury related to iodinated contrast significantly increases morbidity and mortality after angiography or angioplasty. According to registries, its prevalence can vary from 2% in low-risk population to up to 50% in high-risk subjects. Its risk factors include previous renal failure, diabetes, age, and the amount/type of contrast used. As a preventive measure, international

TCT 2022

TCT 2022 | Pulmonary Artery Denervation in Primary Pulmonary Hypertension

Primary Pulmonary Hypertension is behind multiple hospitalizations and pulmonary transplants. Even though its treatment has been advanced, many patients will not respond well.  The PADN-CFDA randomized 128 patients, 63 received pulmonary denervation (PADN) and 65 went to the control group. Primary end point was 6-minute walk distance test at 6 months.  The populations were similar,

TCT 2022

SYMPLICITY HTN-3 Trial. Evolution at 3 Years

The SYMPLICITY 3-year outcomes are out. Bear in mind this is the largest study we have had so far.  It included 535 patients. 364 received renal denervation (RDN) and 171 went to the control group.  At 36-month followup, 101 patients crossed over.  The procedure was safe at 36 months, both for patients receiving it at

TCT 2022

TCT 2022 | RADIANCE II Pivotal Trial

Renal denervation has been developed to treat blood hypertension. Even though at present is still not common, with the development of new technology and improved technique, its results are promising.  The RADIANCE II Pivotal included 224 patients. 150 received renal denervation with ultrasound (uRDN) and 74 went to the control group. Efficacy primary end point

¿Se debe tener en cuenta el género para revascularizar el tronco?

Gender Differences and 10-Year Prognosis in STEMI

Coronary artery disease in women usually develops 10 years later than in men, and some evidence suggests women have higher mortality, especially when it comes to ST elevation MI (STEMI). Registries have shown higher mortality both in hospital and at one year follow up.  In part, this difference is observed because of the gap in


RADIANCE-HTN SOLO: Control Durability of BP

In patients with hard-to-control high blood pressure (HBP), both non-pharmacological treatment and lifestyle changes have been useful to improve its control. Renal denevartion (RDN) was assessed as part of this complementary treatment, since some research has shown that this alternative decreases blood pressure (BP) values in different groups treated with either radiofrequency or ultrasound (uRDN).

La endarterectomía precoz parece superior a la angioplastia carotidea en pacientes sintomáticos

Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease

Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that decrease the restenosis rate. Recently, the IMPERIAL study showed greater patency at 1 year and greater freedom from clinically guided revascularization at 2 years in favor of the ELUVIA stent (paclitaxel-eluting fluoropolymer, FP-DES) compared with the ZILVER PTX